Downtown official reflects on successful St. Patrick's Day weekend
Thousands of people made their way to downtown Erie to view the St. Patrick's Day parade, and organizers said it was a huge success.
Over 75 groups marched down State Street in every shade of green for about two hours.
LECOM Health offers Erie's first treatment for Alzheimer's, dementia
Spectators voted Luther Memorial Academy for crowd favorite and Sinnott and Steves Family was voted best float by the Knights and Ladies of St. Patrick.
Organizers said everyone followed safety instructions properly and celebrated well into monday.
Downtown Erie goes green for annual St. Patrick's Day parade
'A lot of the feedback that we got was that it felt like the old days everybody hopping from bar to bar,' said Dave Tamulonis, events and marketing manager for the Erie Downtown Partnership. 'It's about bringing folks downtown getting them to visit the businesses getting them to stick around and have a dinner at a restaurant maybe shop at some of the retail shops so the economic impact of an event like the parade is felt throughout the weekend.'
Tamulonis thanked the community for their support and said they hope to continue making this a great event for Erie.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
9 hours ago
- Business Wire
Party With a Purpose: Republic Bank hosts fifth annual Juneteenth Event to improve health outcomes in West Louisville
LOUISVILLE, Ky.--(BUSINESS WIRE)--Today, Republic Bank & Trust Company ('Republic' or 'the Bank') hosted the fifth annual Juneteenth Event at the Republic Bank Foundation YMCA. Republic partnered with Kentucky African Americans Against Cancer (KAAAC) and other community organizations to offer free screenings and educational resources to improve the health of West Louisville residents. 'Republic Bank welcomes the opportunity to host this important community event each year in celebration of Juneteenth,' Republic Bank President and CEO Logan Pichel said. 'Republic Bank welcomes the opportunity to host this important community event each year in celebration of Juneteenth,' Republic Bank President and CEO Logan Pichel said. 'We are committed to investing in West Louisville, improving the quality of life and enabling the communities we serve to thrive. Not only are we able to help Louisvillians access life-saving health screenings and resources, but today's event offered everyone an opportunity to celebrate with the community.' According to the American Cancer Society, one in eight men will be diagnosed with prostate cancer in their lifetime, with the risk for Black men being significantly higher. Moreover, a recent National Institutes of Health (NIH) study concluded that Black men have a higher prevalence of prostate cancer because of lower prostate exam screening rates. Additionally, the average dental screening costs about $130, and according to the Kentucky Oral Health Coalition, poor oral health is linked to a number of health conditions including heart disease, diabetes, high blood pressure, stroke and Alzheimer's disease. Further, the Centers for Disease Control and Prevention (CDC) reported that the highest prevalence of fatal oral cancers is among Black Americans, and they are three times more likely to have untreated cavities. In addition to free prostate screenings provided by KAAAC, KARE Mobile offered complementary dental screenings for all attendees. Attendees also enjoyed activities, food and vendors operated by Black- and women-owned businesses. 'We're thrilled to celebrate Juneteenth in West Louisville for the fifth year in a row,' Republic Bank Vice President, Inclusion and Diversity Ashley Duncan said. 'We're grateful for our community partners like KAAAC and Kare Mobile that are helping us reach underserved communities and save lives.' About Republic Bank Republic Bancorp, Inc. (the 'Company') is the parent company of Republic Bank & Trust Company (the 'Bank'). The Bank currently has 47 banking centers in communities within five metropolitan statistical areas ('MSAs') across five states: 22 banking centers located within the Louisville MSA in Louisville, Prospect, Shelbyville, and Shepherdsville in Kentucky, and Floyds Knobs, Jeffersonville, and New Albany in Indiana; six banking centers within the Lexington MSA in Georgetown and Lexington in Kentucky; eight banking centers within the Cincinnati MSA in Cincinnati and West Chester in Ohio, and Bellevue, Covington, Crestview Hills, and Florence in Kentucky; seven banking centers within the Tampa MSA in Largo, New Port Richey, St. Petersburg, Seminole, and Tampa in Florida; and four banking centers within the Nashville MSA in Franklin, Murfreesboro, Nashville and Spring Hill, Tennessee. In addition, Republic Bank Finance has one loan production office in St. Louis, Missouri. The Bank offers online banking at The Company is headquartered in Louisville, Kentucky, and as of March 31, 2025, had approximately $7.1 billion in total assets. The Company's Class A Common Stock is listed under the symbol 'RBCAA' on the NASDAQ Global Select Market.
Yahoo
a day ago
- Yahoo
IVF parents are spending thousands to predict their babies' chances of having Alzheimer's, cancer and heart disease
Maybe she's born with it, maybe it's … genetic optimization? Prospective parents using in vitro fertilization (IVF) will soon be able to select embryos based on their potential risk for diseases — including illnesses that develop later in life — thanks to a groundbreaking $5,999 service announced this week by a US biotech company. 'Before there's a heartbeat, there's DNA,' Kian Sadeghi, founder and chief executive of Nucleus Genomics, said in a statement. 'One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage.' The popular fertility treatment involves removing eggs from a woman's ovaries and fertilizing them with sperm in a lab. The resulting embryo — which could be frozen or fresh — is placed into the uterus, where it hopefully implants in the uterine wall and sparks a pregnancy. Before implantation, many IVF clinics already screen embryos for genetic abnormalities — such as extra chromosomes or gene mutations — that can lead to failed implantations, miscarriages, birth defects or inherited disorders. But the first-of-its-kind service from Nucleus Genomics takes things a step further. The company just launched Nucleus Embryo, a new software platform that lets potential parents dig deep into the full genetic blueprint of their embryos before choosing which one to implant. The tool lets IVF patients compare the DNA of up to 20 embryos, screening them for more than 900 conditions — including Alzheimer's, Type 2 diabetes, heart disease and several forms of cancer. It doesn't stop there. The program also flags potential mental health conditions like depression and schizophrenia and even ranks cognitive traits like IQ. Parents can also get a look at cosmetic and physical features, from height, baldness and BMI to eye and hair color. The company isn't promising perfection. Instead, the software generates a so-called polygenic risk score that will give parents the probability of how likely it is an embryo might develop certain traits or diseases. Ultimately, it's up to the parents to decide which qualities matter most to them. For those looking to decode the results, genetic counseling sessions are available. 'Lifespan has dramatically increased in the last 150 years,' Sadeghi told the Wall Street Journal. 'DNA testing to predict and reduce chronic disease can make it happen again.' The practice, known as polygenic embryo screening, is already highly controversial in the medical world, according to a report published by Harvard Law School's Petrie-Flom Center. Critics warn that allowing parents to screen embryos for risks like depression or diabetes could deepen stigma and discrimination against people living with those conditions. Meanwhile, disability advocates argue it promotes the harmful idea that disability is something to be fixed, not a natural part of human diversity. And when it comes to choosing embryos for traits like intelligence or athleticism, critics say we're sliding into designer baby territory — a modern form of eugenics that favors the rich, reinforcing social and healthcare inequalities. Still, the public appears open to some aspects of the tech. A 2023 survey found that 77% of Americans support using it to screen embryos for the likelihood of developing certain physical conditions, while 72% back screening for mental health risks. Proponents argue it's no different from vaccination — a preventive tool, not a judgment on those with the condition. But when it comes to non-medical traits, support drops fast: only 36% back screening embryos for behavioral traits and just 30% for physical features like height or eye color.
Yahoo
a day ago
- Yahoo
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory
We came across a bullish thesis on Alpha Cognition Inc. Common Stock (ACOG) by anygal on r/investing on Reddit. In this article, we will summarize the bulls' thesis on ACOG. Alpha Cognition Inc. Common Stock (ACOG)'s share was trading at $9.33 as of 30th May. ACOG's forward P/E was 26.88 according to Yahoo Finance. A chemist in a laboratory analyzing data from the various therapeutic tests conducted. Alpha Cognition Inc. (NASDAQ: ACOG) represents a potentially overlooked opportunity in the Alzheimer's treatment space, having recently launched its oral drug, Zunveyl, at the end of March. With a current market cap of $150 million and $45 million in cash, the company is targeting the underserved segment of the Alzheimer's population—specifically, the 50% of patients in long-term care (LTC) not taking any current medications due to severe side effects. Unlike other galantamine-based drugs, Zunveyl significantly slows disease progression and improves short-term memory with a markedly better safety profile—only one serious side-effect case was reported in its Phase 3 trials, versus a 50% rate seen in traditional options. The drug's Medicare coverage further eases affordability, lowering monthly out-of-pocket costs to $30–$190. Initial demand appears promising, with nearly 500 patients starting treatment in the first two weeks of launch. Even a modest 1% market penetration into the LTC segment could yield $135 million in annual revenue, with $67.5 million in net income assuming 50% margins. A 5% penetration would put net income at $675 million, dwarfing the current valuation. Alpha Cognition has also secured a distribution deal with a major Chinese pharmaceutical firm, creating a royalty-based revenue stream in Asia. While the upside is substantial, key risks remain—most notably, the emergence of unforeseen serious side effects post-launch, which could lead to FDA scrutiny or suspension of sales. Still, the market's underreaction and the company's positioning as a safer, effective alternative in a high-need space make ACOG a high-upside, high-conviction bet for risk-tolerant investors. Previously, we have covered ACOG in March 2025 wherein we summarized a by BullishDoctor on Twitter. The user highlighted that Alpha Cognition Inc.'s drug ZUNVEYL addressed the major side effects of existing Alzheimer's treatments, making it highly tolerable and poised for adoption in long-term care facilities, a $2 billion market. The company was pre-revenue but launched in March 2025 with strong physician support, a nearly complete sales force, and promising catalysts like a Phase 4 study and sublingual formulation, projecting breakeven within three years. Since our last coverage, the stock is up 61% as of 30th May. Alpha Cognition Inc. Common Stock (ACOG) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 8 hedge fund portfolios held ACOG at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of ACOG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
